Vioxx (CAS 162011-90-7)
See product citations (3)
QUICK LINKS
Vioxx is extensively studied in chemical research for its interactions with enzyme systems, specifically how it influences cyclooxygenase enzymes. This focus on enzyme interaction helps to elucidate the mechanisms by which Vioxx affects cellular processes related to enzyme function. In research applications, Vioxx is used to understand the biochemical pathways involved in enzyme inhibition, which has implications for the study of similar compounds. Additionally, Vioxx is employed in studies aimed at understanding its binding affinity and kinetics with various biological molecules. The compound is also a subject in materials science research, where it is used in the development of detection systems for biochemical assays, further contributing to advancements in bioanalytical techniques.
Vioxx (CAS 162011-90-7) References
- The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. | Prasit, P., et al. 1999. Bioorg Med Chem Lett. 9: 1773-8. PMID: 10406640
- Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. | Chan, CC., et al. 1999. J Pharmacol Exp Ther. 290: 551-60. PMID: 10411562
- Rofecoxib. | Scott, LJ. and Lamb, HM. 1999. Drugs. 58: 499-505; discussion 506-7. PMID: 10493277
- [Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)]. | Scheen, AJ. 2000. Rev Med Liege. 55: 751-3. PMID: 11014111
- Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer. | Evans, JF. 2003. Am J Clin Oncol. 26: S62-5. PMID: 12902858
- [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. | Scheen, AJ. 2004. Rev Med Liege. 59: 565-9. PMID: 15623076
- Rofecoxib for osteoarthritis. | Garner, SE., et al. 2005. Cochrane Database Syst Rev. 2005: CD005115. PMID: 15654705
- The safety of rofecoxib. | Burnier, M. 2005. Expert Opin Drug Saf. 4: 491-9. PMID: 15934855
- Patient retention in a clinical trial: a lesson from the rofecoxib (VIOXX) study. | Mor, M., et al. 2006. Dig Dis Sci. 51: 1175-8. PMID: 16944005
- Dual carbonic anhydrase--cyclooxygenase-2 inhibitors. | Dogné, JM., et al. 2007. Curr Top Med Chem. 7: 885-91. PMID: 17504133
- Vioxx redux - or how I learned to worry about industry-sponsored clinical trials. | Brophy, JM. 2016. Indian J Med Ethics. 1: 224-226. PMID: 27608487
- Pharmacologically pertinent period of effect (PPPE). | Suissa, M. and LeLorier, J. 2020. Pharmacoepidemiol Drug Saf. 29 Suppl 1: 61-67. PMID: 30628139
- Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. | Stiller, CO. and Hjemdahl, P. 2022. J Intern Med. 292: 557-574. PMID: 35585779
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Vioxx, 100 mg | sc-208486 | 100 mg | $190.00 |